In selected patients with ocular adnexal MALT lymphoma, no initial therapy might be an acceptable approach, because 70% of patients remained untreated at a median of 8.6 years, and their survival was comparable to that of reports on immediate therapy.

Summary:treatment with ganciclovir combined with immune globulin, it remains an important cause of morbidity and mortality after allogeneic BMT. 3-7Cytomegalovirus (CMV) infection and CMV-associated disease were monitored using the CMV antigenemia Major risk factors for CMV infection and CMV-associated disease include seropositivity for CMV before transassay in 72 patients who received allogeneic bone marrow transplantation (BMT), and their incidences were plant and the development of acute graft-versus-host disease (GVHD), which is closely related to genetic disparity compared between related and unrelated donor transplant patients. The incidence of CMV infection after between recipients and donors.

Although the total number of patients was relatively small, the detailed clinical data analyses presented here revealed several new characteristics of PBL and some aspects that may be unique to Japanese patients.

Summary:with acute myelogenous leukemia (AML). 1,2 However, most will relapse despite consolidation and maintenance chemotherapy. Therefore, post-remission therapy is one of The safety and efficacy of myeloablative therapy followed by autologous peripheral blood stem cell transthe most important issues in the treatment of AML. An increasing number of AML patients have been treated with plantation (ABSCT) for acute myelogenous leukemia (AML) were evaluated in 60 patients. Peripheral blood intensified consolidation chemotherapy, autologous bone marrow transplantation (BMT), or allogeneic BMT. ditioning regimen and graft-versus-leukemia (GVL) effects. 5 Nevertheless, in addition to the requirement of was used for pretransplant conditioning in 13 patients. For the remaining 47 patients, granulocyte colony-HLA-identical marrow donors, transplant-related morbidity and mortality remain the major obstacles to improving stimulating factor (G-CSF) was administered concurrently with the BEA regimen during conditioning.clinical results of allogeneic BMT. In autologous BMT, regimen-related toxicities are fewer, although a GVL effect Unpurged, cryopreserved PBSC containing a median number of 5.4 × 10 8 MNC/kg or 12 × 10 4 CFU-GM/kg cannot be obtained. One randomized study has demonstrated that patients treated with autologous BMT have were reinfused at transplantation. The median number of days to granulocytes exceeding 500/l and last platesuperior disease-free survivals (DFS) to those receiving intensive chemotherapy alone.3 let transfusion were 15 (8-44) and 24 (0-Ͼ180), respectively. The 3-year probabilities of disease-free survival Recently, autologous peripheral blood stem cell transplantation (ABSCT) has begun to replace autologous BMT (DFS) and relapse were 78.6 and 21.4% for patients transplanted in first remission, 29.6 and 64.4% for those because of rapid engraftment and low transplant-related mortality. 6-11 However, high relapse rates have been in second or third remission, and 11.1 and 77.8% for those in relapse, respectively. There were no transplantreported after ABSCT for AML. from all patients or responsible family members.

The majority of patients with POAML showed the behaviors of localized and indolent diseases. Our preliminary observation that no initial therapy is an acceptable approach for selected patients was confirmed. Considering the possible heterogeneity of POAML among initial sites, further investigations are warranted.